Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
Kathryn Lagrue, Alexandre F. Carisey, David J. Morgan, et al.
Blood (2015) Vol. 126, Iss. 1, pp. 50-60
Open Access | Times Cited: 119

Showing 1-25 of 119 citing articles:

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
Gilles Salles, Johannes Duell, Eva González‐Barca, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 7, pp. 978-988
Open Access | Times Cited: 431
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
Weilei Hu, Guosheng Wang, Dongsheng Huang, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 360
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
John P. Leonard, Marek Trnĕný, Koji Izutsu, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 14, pp. 1188-1199
Open Access | Times Cited: 343
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Franck Morschhauser, Nathan Fowler, Pierre Feugier, et al.
New England Journal of Medicine (2018) Vol. 379, Iss. 10, pp. 934-947
Open Access | Times Cited: 312
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Sarah A. Holstein, Philip L. McCarthy
Drugs (2017) Vol. 77, Iss. 5, pp. 505-520
Open Access | Times Cited: 193
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Vanessa Carla Monteiro Pinto, Rui Bergantim, Hugo R. Caires, et al.
Cancers (2020) Vol. 12, Iss. 2, pp. 407-407
Open Access | Times Cited: 190
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma
Nina Shah, Li Li, Jessica M McCarty, et al.
British Journal of Haematology (2017) Vol. 177, Iss. 3, pp. 457-466
Open Access | Times Cited: 182
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
Nicholas A. Maskalenko, Dmitry Zhigarev, Kerry S. Campbell
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 8, pp. 559-577
Open Access | Times Cited: 135
NK cell education via nonclassical MHC and non-MHC ligands
Yuke He, Zhigang Tian
Cellular and Molecular Immunology (2016) Vol. 14, Iss. 4, pp. 321-330
Open Access | Times Cited: 148
Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects
Barbara Bassani, Denisa Baci, Matteo Gallazzi, et al.
Cancers (2019) Vol. 11, Iss. 4, pp. 461-461
Open Access | Times Cited: 142
Myeloid-derived suppressor cells: The green light for myeloma immune escape
Ehsan Malek, Marcos de Lima, John J. Letterio, et al.
Blood Reviews (2016) Vol. 30, Iss. 5, pp. 341-348
Open Access | Times Cited: 120
Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
Aviad Ben‐Shmuel, Guy Biber, Mira Barda‐Saad
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 117
Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance
Alessandra Zingoni, Cinzia Fionda, Cristiana Borrelli, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 113
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
Kerry S. Campbell, Adam D. Cohen, Tatiana Pazina
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 106
Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells
Evelyn Ojo, Ashish Sharma, Ruifu Liu, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 94
Role of the tumor microenvironment in mature B-cell lymphoid malignancies
Nathan Fowler, Chan Y. Cheah, Randy D. Gascoyne, et al.
Haematologica (2016) Vol. 101, Iss. 5, pp. 531-540
Open Access | Times Cited: 93
Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches
Sebastian Carotta
Frontiers in Immunology (2016) Vol. 7
Open Access | Times Cited: 92
Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future
Margaret Lamb, Hemalatha G. Rangarajan, Brian P. Tullius, et al.
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 59
Different evasion strategies in multiple myeloma
Chaofan Wang, Wanting Wang, Moran Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression
Massimo Giuliani, Bassam Janji, Guy Berchem
Oncotarget (2017) Vol. 8, Iss. 14, pp. 24031-24044
Open Access | Times Cited: 83
The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms
Tatiana Pazina, Ashley M. James, Alexander W. MacFarlane, et al.
OncoImmunology (2017) Vol. 6, Iss. 9, pp. e1339853-e1339853
Open Access | Times Cited: 72
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis
Bruno Paiva, María‐Victoria Mateos, Luis Ignacio Sánchez‐Abarca, et al.
Blood (2015) Vol. 127, Iss. 9, pp. 1151-1162
Open Access | Times Cited: 70
Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma
Chao Niu, Haofan Jin, Min Li, et al.
Oncotarget (2016) Vol. 8, Iss. 4, pp. 5954-5964
Open Access | Times Cited: 66
Emerging biomarkers in Multiple Myeloma: A review
Nidhi Gupta, Aparna Sharma, Alpana Sharma
Clinica Chimica Acta (2019) Vol. 503, pp. 45-53
Closed Access | Times Cited: 59
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors
Kerry A. Whalen, Kavya Rakhra, Naveen K. Mehta, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top